The Activity Domain Theory - Informing the Alignment of Business and Knowledge Strategies

Lars Taxén

DOI: https://doi.org/10.4018/978-1-59904-486-6.CH012

Abstract:In this chapter, the activity domain theory is introduced as a theoretical lens for guiding the alignment of business and knowledge strategies. Alignment is focused around the activity domain, whic ...

What problem does this paper attempt to address?

Evaluation of a Tumor-Targeting Oligosaccharide Nanosystem in BNCT on an Orthotopic Hepatocellular Carcinoma Model.

Qiyao Yang,Qi Dai,Xiaoyan Bao,Yi Zhou,Yiying Lu,Haiqing Zhong,Linjie Wu,Yinglu Guo,Lihong Liu,Xin Tan,Yiyi Xia,Min Han,Qichun Wei

DOI: https://doi.org/10.1021/acs.molpharmaceut.2c00771

2023-01-01

Molecular Pharmaceutics

Abstract:Boron neutron capture therapy (BNCT) is becoming a promising radiation treatment technique dealing with tumors due to its cellular targeting specificity. In this article, based on the biocompatible chitosan oligosaccharide (COS), we designed a boron delivery system using carborane (CB) as a boron drug with cRGD peptide modification and paclitaxel (PTX) loaded in the hydrophobic core. The nanoparticles (cRGD-COS-CB/PTX) realized the boron delivery into tumor sites with an enhanced permeability and retention (EPR) effect and an active targeting effect achieved by the cRGD-integrin interaction on the surface of tumor cells. The uniform spherical nanoparticles can be selectively taken by hepatoma cells rather than normal hepatocytes. experiments showed that the nanoparticles had a targeting effect on tumor sites in both subcutaneous and orthotopic tumor models, which was an encouraging result for radiotherapy for liver cancer. To sum up, the nanoparticles we produced proved to be promising dual-functionalized nanoparticles for radiotherapy and chemotherapy.
Intratumoral Transforming Boron Nanosensitizers for Amplified Boron Neutron Capture Therapy

Liping Li,Mixue Wang,Qian Zhao,Peirong Bai,Haotian Hao,Zizhu Zhang,Tong Liu,Yongzhen Yang,Kanyi Pu,Ruiping Zhang

DOI: https://doi.org/10.1002/anie.202413232

2024-11-29

Angewandte Chemie International Edition

Abstract:Boron neutron capture therapy (BNCT) is an advanced binary tumor-cell-selected heavy-particle radiotherapy used for treating invasive malignant tumors. However, its clinical applications have been impeded by the rapid metabolism and insufficient tumor-specific accumulation of boron agents. To tackle this issue, we develop a smart boron nanosensitizer (BATBN) capable of transforming its size in response to cancer biomarker for optimal balance between penetration and retention of boron-10 for BNCT. BATBN comprises an ultrasmall boron quantum dots (BQD) core (4 nm) conjugated with cell-penetrating peptides, which facilitates its cellular uptake and deep tumor penetration. In the tumor microenvironment, the tumor biomarker can specifically initiate a self-condensation reaction of BATBN, leading to the formation of larger-sized nanoaggregates. Due to such a specific intratumoral transformation, BATBN demonstrate a 2.4-fold increase in intratumoral boron concentration and a 5.0-fold increase in tumor retention time compared to the BQDs. Thus, the relative tumor volume of the BATBN-treatment group is 2.7-fold smaller than that of BQDs in preclinical tumor models after 21 days of neutron irradiation treatment. This study presents a supramolecular strategy to endow BNCT agents with the biomarker-activated size interconversion, permitting precise and efficient BNCT for cancer treatment.

chemistry, multidisciplinary
Boron Neutron Capture Therapy in Clinical Application:Progress and Prospect

Jing Xu,Junjie Wang,Qichun Wei

DOI: https://doi.org/10.1360/tb-2021-0907

2021-01-01

Chinese Science Bulletin (Chinese Version)

Abstract:Boron neutron capture therapy (BNCT) is an emerging radiotherapeutic modality aimed at selectively concentrating boron compounds in tumor cells and then subjecting the tumor cells to neutron beam radiation. Treatment with BNCT is based on the nuclear capture and fission reactions that occur when nonradioactive boron-10 (B-10) is irradiated with neutrons to yield an alpha particle (helium, He-4) and a recoiling lithium-7 (Li-7) nuclei. The He-4 particle has a range of 9 mu m and the Li-7 particle 5 mu m in tissue. In theory, the short range of this reaction limits the damage to malignant cells while sparing adjacent normal cells. The development of BNCT is still constrained by the progress in developing boron delivery agents with a high tumor uptake, low normal tissue uptake, and optimizing the dosing paradigms and quantitative estimation of the B-10 concentrations. It is widely recognized that the second generation boron-containing agents, sodium borocaptate (BSH) and boronophenylalanine (BPA), are less than ideal. New and more effective boron-containing agents are urgently required for clinical use to deliver the requisite amounts of boron to tumor cells. The delivery of boron-containing agent can also be optimized to improve cancer cell uptake and subcellular distribution. Additionally, it is crucial to design high intensity neutron sources and establish hospital-based BNCT. Compared with nuclear reactors. accelerator-based neutron sources are more realistic to be applied in clinical practice. In future, the critical issues regarding novel boron-containing agents, the appropriate delivery strategies, and neutron sources of BNCT for clinical use must be addressed. Two clinical trials with newly diagnosed glioblastoma have been reported. BNCT alone after surgery provided a mean survival time of 17.7 and 19.5 months respectively. The survival outcomes were good as compared to the current standard of care which is post-operation fractionated radiotherapy with concomitant and adjuvant TMZ. Several clinical studies of BNCT in the treatment of recurrent head and neck cancer have been reported. with high response rate and acceptable toxicity. To date, BNCT has been clinically evaluated as an alternative to conventional radiotherapy for the treatment of several tumor types, including newly diagnosed glioblastoma. recurrent glioma, recurrent head and neck tumors, meningioma, malignant melanoma. and liver metastasis. Recently, accelerator-based neutron source has been used in clinical trials for recurrent malignant gliomas and head & neck cancers. Although initial results with BNCT are promising, high-quality prospective clinical trials are still lacking. Well-designed phase II/III clinical research is necessary to define the efficacy and safety of BNCT in various tumor types. Meanwhile, studies comparing the outcomes of BNCT with other standards of care are needed for the further development of BNCT. Based on the previous studies, the BNCT clinical trials in glioblastoma can be initiated with newly diagnosed glioblastoma patients. For other tumor types, late-stage patients with recurrent or metastatic disease after the first-line treatment might be recruited. Last but not the least, in the era of comprehensive treatment for malignant tumor. it is necessary to explore the combined treatment mode of BNCT. For the future research, BNCT may be coupled with a variety of anti-tumor modalities, including traditional photon radiotherapy, immunotherapy, targeted therapy and chemotherapy. It is also possible to explore a variety of drug delivery methods to improve the uptake of boron-containing agents by tumor sites. Multidisciplinary model is needed to jointly promote BNCT to become a routine clinical treatment modality.
Development of purification methods for tumor targeted polyplexes applied in vivo

Julia Fahrmeir

2007-06-13

Abstract:Diese Dissertation wurde selbständig, ohne unerlaubte Hilfe erarbeitet.
Catalytic Modulation of the Tumor Microenvironment Using Cascade Enzymes for Synergistic Boron Neutron Capture Therapy in the Treatment of Gliomas

Qi Dai,QiYao Yang,Zhicheng Zhang,Yaxin Qin,Xiaoyan Sun,Xiaoyan Bao,Linjie Wu,Ruolin Jiang,Xin Tan,Xufang Ying,Zhiqing Ben,Hefa Huang,Rui Quan,Ruirong Zhuang,Benhua Xu,Min Han,Qichun Wei

DOI: https://doi.org/10.21203/rs.3.rs-4939120/v1

2024-01-01

Abstract:Glioma is the most common primary malignant tumor of the central nervous system. Despite traditional treatments such as surgical resection, combined postoperative chemotherapy, and radiotherapy, it remains challenging to significantly improve the long-term survival rate of patients. This is primarily due to the incomplete surgical removal of the tumor and its resistance to radiotherapy. Boron neutron capture therapy (BNCT) is a radiotherapy that can selectively kill tumor cells. Current research has demonstrated that BNCT offers effective local disease control for gliomas and head and neck tumors. However, the existing boron-containing drugs are still unsatisfactory due to their low boron content and poor targeting ability. The synergistic treatment has provided new ideas for the development of BNCT, and the emergence of nanosystems offers the possibility of prolonged retention and pinpoint delivery of boron drugs in the tumor cites. The unique tumor microenvironment(TME) of gliomas, characterized by the blood brain barrier (BBB), oxidative stress, hypoxia and angiogenesis, renders conventional treatments ineffective and poor prognosis. Therefore, to combine the TME regulation and BNCT therapy, we prepared a stable nanosystem in this study. It is a borane-contained cationic liposome modified with cRGD peptide which enhances the tumor-targeting ability. And the enzymes Lactate oxidase(LOX) and Catalase(CAT) are absorbed on the surface of the nanosystem which reduce the concentration of lactic acid through a cascade reaction to generate O2 and decrease the protein expression level of HIF-1α. This nanosystem exhibited a more potent anti-tumor effect both in vitro and in vivo. Also it reduced tumor stemness in vivo, which improves the prognosis. Therefore, the novel nanosystem combined microenvironment regulation therapy and BNCT shows the great potential application in anti-tumor treatment.
Boron delivery agents for neutron capture therapy of cancer

Rolf F Barth,Peng Mi,Weilian Yang

DOI: https://doi.org/10.1186/s40880-018-0299-7

2018-06-19

Abstract:Boron neutron capture therapy (BNCT) is a binary radiotherapeutic modality based on the nuclear capture and fission reactions that occur when the stable isotope, boron-10, is irradiated with neutrons to produce high energy alpha particles. This review will focus on tumor-targeting boron delivery agents that are an essential component of this binary system. Two low molecular weight boron-containing drugs currently are being used clinically, boronophenylalanine (BPA) and sodium borocaptate (BSH). Although they are far from being ideal, their therapeutic efficacy has been demonstrated in patients with high grade gliomas, recurrent tumors of the head and neck region, and a much smaller number with cutaneous and extra-cutaneous melanomas. Because of their limitations, great effort has been expended over the past 40 years to develop new boron delivery agents that have more favorable biodistribution and uptake for clinical use. These include boron-containing porphyrins, amino acids, polyamines, nucleosides, peptides, monoclonal antibodies, liposomes, nanoparticles of various types, boron cluster compounds and co-polymers. Currently, however, none of these have reached the stage where there is enough convincing data to warrant clinical biodistribution studies. Therefore, at present the best way to further improve the clinical efficacy of BNCT would be to optimize the dosing paradigms and delivery of BPA and BSH, either alone or in combination, with the hope that future research will identify new and better boron delivery agents for clinical use.
Application of Nitroimidazole-Carbobane-Modified Phenylalanine Derivatives as Dual-Target Boron Carriers in Boron Neutron Capture Therapy

Ruixi Li,Juanjuan Zhang,Jingxuan Guo,Yue Xu,Kunyuan Duan,Jinrong Zheng,Hao Wan,Zhenwei Yuan,Haiyan Chen

DOI: https://doi.org/10.1021/acs.molpharmaceut.9b00898

2020-01-06

Abstract:Boron neutron capture therapy (BNCT) has received extensive attention as noninvasive cell-level oncotherapy for treating solid cancer tumors. However, boron-containing drugs such as l-boronophenylalanine (BPA) and sodium borocaptate have low boron content and/or poor tumor-targeting ability, limiting their application. In this study, we designed and synthesized a series of nontoxic, dual-target boron carriers (B139, B142, and B151) with the ability to accumulate specifically in tumor cells. We found that the B139 uptake into hypoxic tumor regions was high, with a 70-fold boron content compared to BPA. In addition, in vivo observation showed that B139 can be trapped in tumor cells for a prolonged period and maintains an effective therapeutic concentration, with a peak boron concentration of 50.7 μg/g and a high tumor: blood boron ratio of >3, achieving ideal BNCT conditions. Cytotoxicity evaluation in mice further proved that B139 is safe and reliable. Therefore, B139 has great potential for BNCT application as a dual-target, safe, and efficient boron carrier.
Advancements in Tumor Targeting Strategies for Boron Neutron Capture Therapy

Micah John Luderer,Pilar de la Puente,Abdel Kareem Azab

DOI: https://doi.org/10.1007/s11095-015-1718-y

Abstract:Boron neutron capture therapy (BNCT) is a promising cancer therapy modality that utilizes the nuclear capture reaction of epithermal neutrons by boron-10 resulting in a localized nuclear fission reaction and subsequent cell death. Since cellular destruction is limited to approximately the diameter of a single cell, primarily only cells in the neutron field with significant boron accumulation will be damaged. However, the emergence of BNCT as a prominent therapy has in large part been hindered by a paucity of tumor selective boron containing agents. While L-boronophenylalanine and sodium borocaptate are the most commonly investigated clinical agents, new agents are desperately needed due to their suboptimal tumor selectivity. This review will highlight the various strategies to improve tumor boron delivery including: nucleoside and carbohydrate analogs, unnatural amino acids, porphyrins, antibody-dendrimer conjugates, cationic polymers, cell-membrane penetrating peptides, liposomes and nanoparticles.
Boron delivery for boron neutron capture therapy targeting a cancer-upregulated oligopeptide transporter

Junji Miyabe,Ryuichi Ohgaki,Keijiro Saito,Ling Wei,Lili Quan,Chunhuan Jin,Xingming Liu,Suguru Okuda,Shushi Nagamori,Hiroshi Ohki,Kazuo Yoshino,Hidenori Inohara,Yoshikatsu Kanai

DOI: https://doi.org/10.1016/j.jphs.2019.01.012

Abstract:Boron neutron capture therapy (BNCT) is a radiotherapy utilizing the neutron capture and nuclear fission reaction of 10B taken up into tumor cells. The most commonly used boron agent in BNCT, p-borono-l-phenylalanine (BPA), is accumulated in tumors by amino acid transporters upregulated in tumor cells. Here, by using dipeptides of BPA and tyrosine (BPA-Tyr and Tyr-BPA), we propose a novel strategy of selective boron delivery into tumor cells via oligopeptide transporter PEPT1 upregulated in various cancers. Kinetic analyses indicated that BPA-Tyr and Tyr-BPA are transported by oligopeptide transporters, PEPT1 and PEPT2. The intrinsic oligopeptide transport activity in tumor cells clearly correlated with PEPT1 protein expression level but not with PEPT2, suggesting that PEPT1 is the predominant oligopeptide transporter at least in tumor cell lines. Furthermore, using BPA-Tyr and Tyr-BPA, boron was successfully delivered into PEPT1-expressing pancreatic cancer AsPC-1 cells via a PEPT1-mediated mechanism. Intravenous administration of BPA-Tyr into the mice bearing AsPC-1 xenograft tumors resulted in significant boron accumulation in the tumors. It is proposed that the oligopeptide transporters, especially PEPT1, are promising candidates for molecular targets of boron delivery in BNCT. The BPA-containing dipeptides would have a potential for the development of novel boron carriers targeting PEPT1.
Boronotyrosine, a Borylated Amino Acid Mimetic with Enhanced Solubility, Tumor Boron Delivery, and Retention for the Re-emerging Boron Neutron Capture Therapy Field

Arthur Raitano,Tioga Martin,Chunying Zhang,Maria-Christina Malinao,Linnette Capo,Maki Ikeura,Rebecca Carroll,Jason C Quintana,Samkeliso Dlamini,Leila Kulenovic,Eva Jahanshir,Sohye Kang,Karen Morrison,Michael Torgov,Kendall Morrison

DOI: https://doi.org/10.1021/acs.jmedchem.3c01265

2023-10-12

Abstract:Boron neutron capture therapy (BNCT) is a re-emerging binary cellular level cancer intervention that occurs through the interaction of a cancer-specific 10boron (10B) drug and neutrons. We created a new 10B drug, 3-borono-l-tyrosine (BTS), that improves on the characteristics of the main historical BNCT drug 4-borono-l-phenylalanine (BPA). BTS has up to 4 times greater uptake in vitro than BPA and increased cellular retention. Like BPA, BTS uptake is mediated by the l-type amino acid transporter-1 (LAT1) but is less sensitive to natural amino acid competition. BTS can be formulated and bolus dosed at much higher levels than BPA, resulting in 2-3 times greater boron delivery in vivo. Fast blood clearance and greater tumor boron delivery result in superior tumor-to-blood ratios. BTS boron delivery appears to correlate with LAT1 expression. BTS is a promising boron delivery drug that has the potential to improve modern BNCT interventions.
Handwashing Behaviors in Food Service Establishment Restrooms: An Observational Study

Jaemin Cha,Carl P. Borchgrevink,Seunghyun Kim

Abstract:The Centers for Disease Control and Prevention (CDC) identified poor handwashing as a main factor in foodborne illness outbreaks (ServSafe, 2009). They suggested that failure to wash hands, or inadequate washing of hands, contributes to almost 50% of all foodborne illness outbreaks. We conducted an observational study of diners’ handwashing behaviors in restaurant restrooms in terms of gender, handwashing signage, sink cleanliness conditions, and time. Our goal was to explore predictors of proper handwashing behaviors to promote better handwashing compliance.
Boron Neutron Capture Therapy: Current Status and Challenges

Song Wang,Zhengchao Zhang,Lele Miao,Yumin Li

DOI: https://doi.org/10.3389/fonc.2022.788770

IF: 4.7

2022-03-31

Frontiers in Oncology

Abstract:Boron neutron capture therapy (BNCT) is a re-emerging therapy with the ability to selectively kill tumor cells. After the boron delivery agents enter the tumor tissue and enrich the tumor cells, the thermal neutrons trigger the fission of the boron atoms, leading to the release of boron atoms and then leading to the release of the α particles ( 4 He) and recoil lithium particles ( 7 Li), along with the production of large amounts of energy in the narrow region. With the advantages of targeted therapy and low toxicity, BNCT has become a unique method in the field of radiotherapy. Since the beginning of the last century, BNCT has been emerging worldwide and gradually developed into a technology for the treatment of glioblastoma multiforme, head and neck cancer, malignant melanoma, and other cancers. At present, how to develop and innovate more efficient boron delivery agents and establish a more accurate boron-dose measurement system have become the problem faced by the development of BNCT. We discuss the use of boron delivery agents over the past several decades and the corresponding clinical trials and preclinical outcomes. Furthermore, the discussion brings recommendations on the future of boron delivery agents and this therapy.

oncology
Boron-peptide conjugates with angiopep-2 for boron neutron capture therapy

Jing Xiang,Lin Ma,Jianfei Tong,Nan Zuo,Weitao Hu,Yupeng Luo,Junqi Liu,Tianjiao Liang,Qiushi Ren,Qi Liu

DOI: https://doi.org/10.3389/fmed.2023.1199881

2023-06-01

Abstract:Boron neutron capture therapy (BNCT) induces intracellular nuclear reaction to destroy cancer cells during thermal neutron irradiation. To selectively eliminate cancer cells but avoid harmful effects on normal tissues, novel boron-peptide conjugates with angiopep-2, namely ANG-B, were constructed and evaluated in preclinical settings. Boron-peptide conjugates were synthesized using solid-phase peptide synthesis, and the molecular mass was validated by mass spectrometry afterwards. Boron concentrations in 6 cancer cell lines and an intracranial glioma mouse model after treatments were analyzed by inductively coupled plasma atomic emission spectroscopy (ICP-AES). Phenylalanine (BPA) was tested in parallel for comparison. In vitro treatment with boron delivery peptides significantly increased boron uptake in cancer cells. BNCT with 5 mM ANG-B caused 86.5% ± 5.3% of clonogenic cell death, while BPA at the same concentration caused 73.3% ± 6.0% clonogenic cell death. The in vivo effect of ANG-B in an intracranial glioma mouse model was evaluated by PET/CT imaging at 31 days after BNCT. The mouse glioma tumours in the ANG-B-treated group were shrunk by 62.9% on average, while the BPA-treated tumours shrank by only 23.0%. Therefore, ANG-B is an efficient boron delivery agent, which has low cytotoxicity and high tumour-to-blood ratio. Based on these experimental results, we expected that ANG-B may leverage BNCT performance in clinical applications in future.
Fluorinated BPA derivatives enhanced 10B delivery in tumors

Dandan Ding,Shushan Mo,Qishan Li,Fei Wang,Xueyi Wang,Caiwen Ou,Zhenhua Li

DOI: https://doi.org/10.1039/d4tb00846d

IF: 7.571

2024-05-22

Journal of Materials Chemistry B

Abstract:Boron neutron capture therapy (BNCT) is an emerging approach for treating malignant tumors with binary targeting, but its clinical application has been hampered by insufficient 10B accumulation in tumors, low 10B concentration ratios of tumor-to-blood (T/B) and tumor-to-normal tissue (T/N). Herein, we developed fluorinated BPA derivatives with different fluorine groups as boron delivery agents for providing sufficient 10B accumulation in tumors and enhancing T/B and T/N ratios. Our findings demonstrated fluorinated BPA derivatives had good biological safety. Furthermore, fluorinated BPA derivatives showed improved 10B accumulation in tumors, and enhanced T/B and T/N ratios compared to clinical boron drug fructose-BPA (f-BPA). In particular, in the B16-F10 tumor-bearing mice, fluorinated BPA derivatives met the requirements for clinical BNCT even at half of the clinical dose. Thus, fluorinated BPA derivatives are potentially effective boron delivery agents for clinical BNCT in melanoma.

materials science, biomaterials
Engineering a potent boron-10-enriched polymeric nanoparticle for boron neutron capture therapy

Wei-Jen Chan,Sasinan Bupphathong,Han-Lin Cho,Venkanagouda S Goudar,Sina Dehestani,Chi-Shiun Chiang,Fan-Gang Tseng

DOI: https://doi.org/10.2217/nnm-2022-0330

Abstract:Background: Boron neutron capture therapy (BNCT) is a promising cancer treatment that eliminates tumor cells by triggering high-energy radiation within cancer cells. Aim: In vivo evaluation of poly(vinyl alcohol)/boric acid crosslinked nanoparticles (PVA/BA NPs) for BNCT. Materials & methods: PVA/BA NPs were synthesized and intravenously injected into tumor-bearing mice for BNCT. Results: The in vitro boron uptake of PVA/BA NPs in tumor cells was 70-fold higher than the required boron uptake for successful BNCT. In an in vivo study, PVA/BA NPs showed a 44.29% reduction in tumor size compared with clinically used boronophenylalanine for oral cancer in a murine model. Conclusion: PVA/BA NPs exhibited effective therapeutic results for oral cancer treatments in BNCT.
Dual synchronously pumped and synchronously amplified dye lasers.

T. Juhász,J. Kuhl,W. Bron

DOI: https://doi.org/10.1364/OL.13.000577

IF: 3.6

1988-07-01

Optics Letters

Abstract:A dual synchronously pumped and synchronously amplified dye-laser system has been constructed and tested. A regenerative amplifier is used as the amplification source. An amplification factor of 6 × 104 is reached in each of two synchronously pumped dye-laser output beams. Thus, the total incident beam intensity available for two-photon nonlinear excitations reaches an amplification of the order of 4 × 109 times that available from unamplified laser beams.
Radiofrequency Thermal Therapy for Benign Prostatic Hyperplasia by Transurethral Needle Ablation of the Prostate (TUNA): An Update.

S. Myrick,M. Issa

Abstract:Prevalence of symptomatic benign prostatic hypertophy (BPH) is 30% in the sixth decade of life and approaches 50% in the eighth decade of life. Comparable prevalence values are reported in Occidental and Oriental cultures, which suggests the disease susceprible to neither environmental nor cultural favoritism. "Prostatism" is the descriptive word for the BPH constellation of symptoms, which appear as a result of bladder outlets obstructed by an enlarged prostate. In traditional prostatism, prostate growth has a benign etiology. These urologie symptoms may be either irritative (difficulty postponing urination, frequent awakenings at night for urination), obstructive (weak stream, hesitancy), or both. In the context of so much morbidity associated with the BPH symptom complex, this disease is arguably the most bothersome disease for the elderly male. With improvements in healthcare, and with men having longer life expectancies, there is the appreciation of an expanded patient population. It has become possible to heat the prostate with radiofrequency energy (RF) to relieve symptoms associated with BPH using a heating technique called "transurethral needle ablation of the prostate" (TUNA). By both subjective and objective criteria, TUNA theraphy to the prostate for BPH compares favorably with traditional surgical treatment. Now the durability of the TUNA treatment is demonstrated beyond three years.
Theranostics in Boron Neutron Capture Therapy

Wolfgang A G Sauerwein,Lucie Sancey,Evamarie Hey-Hawkins,Martin Kellert,Luigi Panza,Daniela Imperio,Marcin Balcerzyk,Giovanna Rizzo,Elisa Scalco,Ken Herrmann,PierLuigi Mauri,Antonella De Palma,Andrea Wittig

DOI: https://doi.org/10.3390/life11040330

2021-04-10

Abstract:Boron neutron capture therapy (BNCT) has the potential to specifically destroy tumor cells without damaging the tissues infiltrated by the tumor. BNCT is a binary treatment method based on the combination of two agents that have no effect when applied individually: 10B and thermal neutrons. Exclusively, the combination of both produces an effect, whose extent depends on the amount of 10B in the tumor but also on the organs at risk. It is not yet possible to determine the 10B concentration in a specific tissue using non-invasive methods. At present, it is only possible to measure the 10B concentration in blood and to estimate the boron concentration in tissues based on the assumption that there is a fixed uptake of 10B from the blood into tissues. On this imprecise assumption, BNCT can hardly be developed further. A therapeutic approach, combining the boron carrier for therapeutic purposes with an imaging tool, might allow us to determine the 10B concentration in a specific tissue using a non-invasive method. This review provides an overview of the current clinical protocols and preclinical experiments and results on how innovative drug development for boron delivery systems can also incorporate concurrent imaging. The last section focuses on the importance of proteomics for further optimization of BNCT, a highly precise and personalized therapeutic approach.
THE CULTURAL IMPLICATIONS OF JUDICIAL SELECTION

B. Ackerman,S. Carter,R. Bork,H. Monaghan

Abstract:The Constitution allows the President to "nominate . .. by and with the Advice and Consent of the Senate... Judges of the supreme Court."' Traditionally, the same types of faces have dominated this political ritual: White men choose other White men to inhabit the corridors of power. As women and minorities have gradually gained political access and representation, however, the President's nomination and the Senate's confirmation hearings have increasingly become starting dramas in which the collisions between race, gender and power are played out. The 1991 nomination and confirmation of Justice Clarence Thomas will go down in history as the first confirmation in which these tensions became evident. The Thomas appointment process ignited a strident debate, within the African American community and the nation as a whole, over the proper definition of "fitness," or a nominee's capacity to serve in a top government position. The issues raised during Thomas' judicial selection process focused on crucial but previously little-asked questions about race and gender. The ensuing national discussion surpassed previous battles over Supreme Court nominations by demonstrating that the confirmation process is neither race-free nor neutral. And how could it be otherwise? President Bush had vaulted Thomas, a seeming cultural anomaly, a Black "neo-conservative," into the national political spotlight by nominating him for the highest judicial position in the land. The arrival of law
Enhanced boron neutron capture therapy (BNCT) through controlled drug release via boron-loaded nanofiber mats

Wenyong Huang,Yongjin Yang,Yong Pan,Shiwei Jing,Yanxin Qi,Yubin Huang

DOI: https://doi.org/10.1007/s12274-024-6721-3

IF: 9.9

2024-06-27

Nano Research

Abstract:Boron neutron capture therapy (BNCT) is a novel binary therapy combining boron targeted drugs and neutron irradiation, which can selectively and effectively kill cancer cells at the cellular scale. Controlled release of boron drug and its accumulation in tumor sites are the crux of BNCT. Here, we developed a 10 B-boric acid ( 10 BA)-loaded nanofiber applying for BNCT by in situ administration. The nanofibers were obtained by electrospinning technique using polyethylene glycol/polylactide (PEO/PLA) block copolymers. By changing the ratio of hydrophilicity to hydrophobicity of the nanofibers, the controlled release and the effective accumulation of boron 10 isotope ( 10 B) were achieved in situ . The 10 B content in tumor could reach to 2540 μg/g, significantly exceeding the required level of 20–50 μg/g for BNCT operation. Utilizing pertinent DNA damage experiments, direct evidence and quantified data of BNCT-induced DNA damage in tumor cells were obtained for the first time. Transcriptome sequencing was employed to predict the molecular mechanisms and potential signaling pathways of BNCT, providing theoretical basis for future combined therapies. The antitumor efficiency of BNCT was demonstrated by establishing mice model of subcutaneous tumor and tumor recurrence. The research presents a novel boron-loaded nanofiber mats for BNCT, which enables controlled drug release and holds significant potential in the treatment of unresectable or postoperative residual tumors.

materials science, multidisciplinary,nanoscience & nanotechnology,physics, applied,chemistry, physical

The Activity Domain Theory - Informing the Alignment of Business and Knowledge Strategies

Evaluation of a Tumor-Targeting Oligosaccharide Nanosystem in BNCT on an Orthotopic Hepatocellular Carcinoma Model.

Intratumoral Transforming Boron Nanosensitizers for Amplified Boron Neutron Capture Therapy

Boron Neutron Capture Therapy in Clinical Application:Progress and Prospect

Development of purification methods for tumor targeted polyplexes applied in vivo

Catalytic Modulation of the Tumor Microenvironment Using Cascade Enzymes for Synergistic Boron Neutron Capture Therapy in the Treatment of Gliomas

Boron delivery agents for neutron capture therapy of cancer

Application of Nitroimidazole-Carbobane-Modified Phenylalanine Derivatives as Dual-Target Boron Carriers in Boron Neutron Capture Therapy

Advancements in Tumor Targeting Strategies for Boron Neutron Capture Therapy

Boron delivery for boron neutron capture therapy targeting a cancer-upregulated oligopeptide transporter

Boronotyrosine, a Borylated Amino Acid Mimetic with Enhanced Solubility, Tumor Boron Delivery, and Retention for the Re-emerging Boron Neutron Capture Therapy Field

Handwashing Behaviors in Food Service Establishment Restrooms: An Observational Study

Boron Neutron Capture Therapy: Current Status and Challenges

Boron-peptide conjugates with angiopep-2 for boron neutron capture therapy

Fluorinated BPA derivatives enhanced 10B delivery in tumors

Engineering a potent boron-10-enriched polymeric nanoparticle for boron neutron capture therapy

Dual synchronously pumped and synchronously amplified dye lasers.

Radiofrequency Thermal Therapy for Benign Prostatic Hyperplasia by Transurethral Needle Ablation of the Prostate (TUNA): An Update.

Theranostics in Boron Neutron Capture Therapy

THE CULTURAL IMPLICATIONS OF JUDICIAL SELECTION

Enhanced boron neutron capture therapy (BNCT) through controlled drug release via boron-loaded nanofiber mats